Expression and purification of internalin a ligand for internalization studies on non-professional phagocytic epithelial cells by Haddad, Natalie
EXPRESSION AND PURIFICATION OF INTERNALIN A LIGAND 
FOR INTERNALIZATION STUDIES ON NON-PROFESSIONAL 




























In Partial Fulfillment 
of the Requirements for the Bachelors of Science Degree 
Biology in the 








Georgia Institute of Technology 
December 2011 
 







 The project discussed in this thesis was carried out in Dr. Todd Sulchek’s 
laboratory in the Parker H. Petit Institute of Bioengineering and Biosciences on the 
Georgia Institute of Technology campus. Project funding was provided by the 2011 Petit 
Undergraduate Research Scholarship Program. I would like to thank my principal 
investigator, Dr. Sulchek, and my graduate student mentor, Patricia Pacheco for their 
visions of the project and continued support throughout the project. I would also like to 
thank my Honors Research Thesis professor Dr. Jung Choi of the Biology Department at 
Georgia Tech for serving as my Biology faculty co-advisor on the project. Lastly, I would 
like to thank Dr. Youn-Hi Woo, one of the researchers of an important preceding study, 
for providing the pGEX-6p-1-InlA plasmid and assistance for some of the methods 
















TABLE OF CONTENTS 
Page 
ACKNOWLEDGMENTS iii 
LIST OF FIGURES v 
LIST OF EQUATIONS                                                                                                     vi 
LIST OF SYMBOLS AND ABBREVIATIONS vii 
ABSTRACT viii 
CHAPTER  
1 Introduction 1 
2 Background Information and Literature Review 5 
3 Materials and Methods 9 
Plasmid Preparation 9 
Plasmid Recovery and Initial DH5α Transformation 9 
Plasmid Purification 10 
Agarose Gel Electrophoresis 11 
OneShot BL21(DE3)pLysS Transformation 12 
InlA-GST Expression 13 
4 Results 15 
Plasmid Recovery and Initial DH5α Transformation 15 
Plasmid Purification 16 
Agarose Gel Electrophoresis 17 
OneShot BL21(DE3)pLysS Transformation 18 
5 Discussion 21 
REFERENCES 25 
 v 
LIST OF FIGURES 
Page 
Figure 1.0: Escherichia coli MAX Efficiency DH5αF`IQ competent cells        
transformed with pGEX-6p-1-InlA plasmid and with control M13mp19RF plasmid 15 
Figure 2.0: Agarose gel electrophoresis analysis from plasmid Purification 17 









LIST OF EQUATIONS 
Page 
Equation 1.0. Calculation of purified plasmid concentration per ml TE buffer after 
QIAGEN midi kit purification of pGEX-6P-1-InlA-1 plasmid from DH5α E. coli 
 cells                                                                                                                                16 
Equation 2.0. Calculation of total yield of pGEX-6P-1-InlA-1 plasmid purified          
using QIAGEN midi kit  16 
Equation 3.0. Calculation of transformation efficiency of One Shot BL21(DE3)        
pLysS expression competent E. coli cells using the average number of colonies                
of BL21 cells transformed with the control ampicillin resistant pUC19 plasmid         















LIST OF SYMBOLS AND ABBREVIATIONS 
 
A260                 Absorbance reading from spectrophotometer at 260 nanometer wavelength 
A600                 Absorbance reading from spectrophotometer at 600 nanometer wavelength 
AmpR                                                                                   Ampicillin antibiotic resistance                                             
BL21                                  One Shot BL21(DE3)pLysS expression competent E. coli cells 
CamR                                                                         Chloramphenicol antibiotic resistance 
DH5α                                                  MAX Efficiency DH5αF`IQ competent E. coli cells 
E-cadherin                                                     Epithelial cadherin surface receptor 
E. coli                                                                      Escherichia coli bacteria  
GST                                                                                               Glutathione S-transferase 
L. monocytogenes                                                               Listeria monocytogenes bacteria 
InlA   Internalin A protein 









Infection by intracellular pathogens is a growing concern as these microorganisms can 
cross their host’s cellular barrier and use the host’s own cellular proteins for replication, 
making treatment very difficult (Kenneth et al., 2008). A further restriction for treatment 
is that a proposed drug must be able to cross the same barriers in order to reach these 
pathogens. Our study investigates the same protein used by a particular intracellular 
pathogen, Listeria monocytogenes, as a possible internalization method for intracellular 
delivery of materials or drugs. A pGEX-6p plasmid vector containing a gene for the 
bacterial surface protein Internalin A (InlA) and a glutathione S-transferase (GST) tag, 
was restored and transformed into Escherichia coli MAX Efficiency DH5αF`IQ 
competent cells in order to increase insert stability and DNA quality. The plasmid was 
then purified and subsequently transformed into One Shot BL21(DE3)pLysS expression 
competent E. coli cells. Thereafter, the InlA-GST fusion protein was expressed in the 
BL21 cells using Isopropyl β-D-1-thiogalactopyranoside (IPTG). It has been shown, 
through selective plating and gel electrophoresis, that the plasmid was successfully 
transformed and purified. Our next steps will be to purify the InlA-GST fusion protein 
using glutathione affinity based chromatography, cleave and remove the GST tag from 
the InlA protein of interest, fluorescently label InlA using Alexa Flour, and bind InlA to 
microbeads of various sizes in a range of densities. We will then carry out internalization 
assays of the InlA-coated beads in different epithelial cell lines to demonstrate the 







Virtually all cells, including unicellular organisms, live in the vicinity of other 
cells. Communication with their neighbors is a fundamental property that influences their 
every function. As a consequence, all cells have signaling mechanisms involved in 
metabolic processes, growth and differentiation, synthesis and secretion of proteins, and 
responding to environmental conditions (Lodish et al., 2008). Signaling is also extremely 
important in the immune response to harmful pathogenic microorganisms and viruses. 
Immune-system cells sense changes in the extracellular environment and are activated 
through their cell-surface receptors. This can take the form of specific antigen recognition 
as in T- and B-lymphocyte activation or general pathogen pattern recognition found in 
innate immune cells such as macrophages, which internalize and destroy pathogens 
through a process known as phagocytosis (Kenneth et al., 2008). The phagocytosis 
process is well studied in “professional” phagocytic cells such as macrophages; however, 
pathogens are often internalized by “non-professional” phagocytes as well, including 
epithelial cells. The mechanisms underlying the process in the later are not as well 
understood (Blanchette et al., 2009; Lecuit, 2005).  
It is known that pathogens that are internalized by non-professional phagocytes 
can take advantage of the host’s cell-surface receptors and signaling pathways which 
result in internalization of the pathogen. Once inside, the pathogen can take advantage of 
more of the host’s cellular proteins and cytoskeleton, aiding its movement and 
replication, (Pizarro-Cerda et al., 2004) and sometimes evade normal immune responses 
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(Kenneth et al., 2008). The costs that these pathogens impose on their hosts are evident in 
harmful diseases that are caused by intracellular pathogens (Barbuddhe & Chakraborty, 
2009). Because of the nature of infection inside of the cell, treatment of these diseases 
can be difficult, as proposed drugs would also need to cross through the cellular 
membrane to combat the pathogen. Further investigation of the mechanisms and proteins 
employed by the very pathogens that are internalized may prove valuable in developing 
novel drug therapies. A model intracellular pathogen is Listeria monocytogenes, a 
bacterium that induces its internalization by binding one of its surface proteins, Internalin 
A (InlA), to an epithelial host cell’s E-cadherin receptor (Bonazzi et al., 2009). 
Under the guidance of Dr. Todd Sulchek and graduate student Patricia Pacheco, I 
have generated the InlA protein for phagocytosis studies on non-professional phagocytic 
epithelial cells. I achieved this by first transforming Escherichia coli MAX Efficiency 
DH5αF`IQ competent cells (Invitrogen, Carlsbad, CA), with a pGEX-6p-1-InlA 
ampicillin resistant (AmpR) plasmid, an extra-chromosomal circular piece of DNA 
containing a gene for InlA and an attached (glutathione S-transferase) GST tag 
(Blanchette et al., 2009). I then purified the plasmid from the DH5α cells using a 
QIAGEN plasmid purification midi kit (QIAEGN, Valencia, CA), and subsequently 
transformed the plasmid once again into One Shot BL21(DE3)pLysS expression 
competent E. coli cells (Invitrogen, Carlsbad, CA). The production of the InlA-GST 
fusion protein was then expressed using Isopropyl β-D-1-thiogalactopyranoside (IPTG). 
MAX Efficiency DH5αF`IQ competent E. coli cells were used because they 
contain recA1 and endA1 mutations which increase insert stability and improve the 
quality of plasmid DNA (Invitrogen, 2006). One Shot BL21(DE3)pLysS expression 
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competent E. coli cells were used to achieve high-efficiency expression of the InlA-GST 
fusion protein gene, which is under the control of a T7 promoter. The BL21 strain 
contains a DE3 lysogen carrying a gene for T7 RNA polymerase under the control of the 
lacUV5 promoter, which ultimately means that expression of T7 RNA polymerase and 
subsequent InlA-GST expression requires Isopropyl β-D-1-thiogalactopyranoside 
(IPTG). In this way, I was able to control when InlA expression was to be carried out 
during the experiment by addition of IPTG to liquid culture of BL21(DE3)pLysS-pGEX-
6P-1-InlA-1 E. coli cells. The BL21 strain used in this study also contains a pLysS 
plasmid, which contains a T7 lysozyme gene responsible for lowering background 
expression level of InlA under control of the T7 promoter. After IPTG is added, however, 
the T7 lysozyme does not affect the expression of InlA-GST (Invitrogen, 2010). The 
pLysS plasmid also contains a chloramphenicol resistance (CamR) gene and a p15A 
origin, allowing it to be compatible with plasmids containing pMB1 origin (Invitrogen, 
2010), including the pBR322- derived pGEX-6P plasmid used in this study. The pGEX-
6P plasmid used carries an ampicillin resistance (AmpR) gene, which allows bacteria 
harboring the pGEX-6P plasmid to grow in the presence of ampicillin antibiotic 
(Blanchette et al., 2009). The pGEX-6P plasmid is a glutathione S-transferase (GST) 
expressing vector with a GST sequence adjacent to the InlA gene so that an InlA-GST 
fusion protein was expressed when IPTG was added. This GST tag allows the fusion 
protein containing the protein of interest, InlA, to be purified from solution by 
glutathione affinity based chromatography, due to the affinity of GST for glutathione 




The future steps in this project will be to purify the InlA-GST fusion protein from 
the BL21 cells using glutathione affinity based chromatography, cleave and remove the 
GST tag from the InlA protein, fluorescently label InlA with Alexa Flour dye, then bind 
InlA to different sizes of microbeads in varying densities by passive adsorption. Finally, 
the InlA functionalized beads will be administered to several epithelial cell line cultures 
in vitro to induce phagocytosis of the beads. Cell internalization assays will be conducted 
in order to compare the effects of ligand density, bead size, and eukaryotic target cell 
versatility and analyzed quantitatively using flow cytometry, and qualitatively using 
fluorescent microscopy. Previous knowledge and studies, discussed in the literature 
review, provide insight into the importance of our research.  
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CHAPTER 2 
BACKGROUND INFORMATION AND LITERATURE REVIEW 
 
Cells respond to their extracellular environment when molecules bind to their 
surface receptor proteins, which activate signal transduction pathways inside the cells 
(Kenneth et al., 2008). A superfamily of cell surface transmembrane glycoproteins which 
participate in cellular adhesion, recognition, and signaling includes the cadherin 
receptors. Classical cadherins, known as Type 1 cadherins, are known to associate with 
the actin cytoskeleton and are found in most solid tissues of the body including the 
epithelial, neural, and vascular endothelial cells (Yap & Goodwin, 2004). Interactions 
between cells and the extracellular matrix are important in allowing cells to aggregate 
into tissues and also for bidirectional communication between the exterior and the interior 
of cells. Many biological processes such as cell survival, proliferation, differentiation, 
and migration depend on this type of cellular communication (Lodish et al., 2008); 
however, this system can also be exploited by harmful pathogens. One of these prominent 
intracellular pathogens is Listeria monocytogenes, the bacterium responsible for a highly 
fatal foodborne disease listeriosis (Barbuddhe & Chakraborty, 2009).  L. monocytogenes 
exploits the host cell’s epithelial cadherin receptor, E-cadherin, as well as its actin 
cytoskeleton in the cytosol, allowing the bacteria to move around freely within the host 
cell (Dramsi et al., 1998). This bacterium uses a surface protein, Internalin A (InlA), to 
interact with the host cell’s E-cadherin receptor. This activates a cellular signaling 
pathway that results in internalization of the bacterium into endothelial eukaryotic cells 
(Bonazzi et al., 2009). A previous study ascertained the crystalline structures of the InlA 
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functional domain both alone and in conjunction with the extracellular, N-terminal 
domain of E-cadherin. E-cadherin is surrounded and recognized by the leucine-rich 
repeat domain of InlA. Researchers in this study were able to probe individual 
interactions by mutagenesis and analytical ultracentrifugation, including a major 
determinant for human susceptibility to L. monocytogenes infection, Pro16 of human E-
cadherin, which is important for intermolecular recognition (Schubert et al., 2002).  
The dangers of L. monocytogenes are highlighted by the fact that it is found in a 
variety of environmental sources, including soil, water, sewage waste, food, and human 
and animal feces (Barbuddhe & Chakraborty, 2009). In fact, a single Listeria outbreak 
was responsible for at least 29 deaths in the United States in the year 2011, due to 
consumption of contaminated Rocky Ford-brand cantaloupes grown and distributed by 
Jensen Farms in Colorado. According to the Centers for Disease Control and Prevention, 
this incident is the deadliest food-borne illness outbreak in the United States since 1924. 
With 139 reported illnesses so far, the death toll is even still rising weeks after the 
cantaloupe recall due to the long incubation period of Listeria, up to two months before 
causing any sign of illness. This is because Listeria is able to thrive and proliferate 
successfully in epithelial cells over a long time and evade the immune system response 
(Weise, 2011). One of the ways in which Listeria can evade the immune system response 
is by preventing the phagosome containing Listeria from fusing with a lysosome, which 
is a crucial step in the phagocytosis process. This step most likely enhances usual host 
defense because the phagolysosome created is very acidic and contains hydrolytic 
enzymes, both properties of which inhibit microbial growth (Blanchette et al., 2009).  
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Infection by intracellular pathogens is a vital concern as these microorganisms 
can use their host’s own cellular proteins for replicating and spreading, making treatment 
very difficult (Kenneth et al., 2008). A further restriction for treatment is that a proposed 
drug must be able to cross the host’s cellular barriers in order to reach these pathogens. 
The key to an efficient internalization option for drug delivery may lie in the machinery 
used by the very pathogens that the drug seeks to combat. Another previous study, in 
which the principle investigator of this current project, Dr. Sulchek, was involved in, has 
shown that microparticles functionalized with InlA can be internalized by non-
phagocytotic epithelial cells. This study developed a method with which to measure and 
decouple particle internalization, phagosomal acidification, and phagosomalendosomal/ 
lysosomal fusion in Madin-Darby Canine Kidney (MDCK) and Caco-2 epithelial cells. 
They independently measured the rates of each step by combining the InlA-coated beads 
with antibody quenching dye, a pH sensitive dye, and an endosomal/lysosomal dye. They 
found the time scales for each step to be 23-32 minutes, 3-4 minutes and 74-120 minutes, 
respectively, for MDCK and Caco-2 epithelial cells (Blanchette et al., 2009). This study 
is important because while phagocytosis has been assessed in “professional” phagocytic 
cells of the immune system such as polymorphonuclear leukocytes, (PMNs), monocytes, 
neutrophils and macrophages, little has been done in the past to examine the process in 
non-professional phagocytic epithelial cells (Blanchette et al., 2009), which are often the 
targets of intracellular pathogens.  
The study done by Blanchette et al, especially, was used as a reference for most of 
the methods in our project. In fact, the pGEX-6p-1-InlA plasmid used in this current 
project was recovered from stored samples remaining from the previous project. The 
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previous researchers amplified the extracellular domain of InlA (the N8 terminal 500 
residues) from genomic DNA of L. monocytogenes, ligated it into a TOP-2.1 vector 
(Invitrogen, Carlsbad, CA), and transformed it into Escherichia coli MAX Efficiency 
DH5αF`IQ competent cells. The researchers selected the amplified product for the insert 
of appropriate direction and digested it with EcoRI and BamHI. Finally, the insert was 
ligated into a GST expression vector, pGEX-6p-1 (Stratagene, La Jolla, CA). They then 
transformed the final plasmid construct, pGEX-6p-1-InlA once again into DH5α E. coli 
and confirmed the final sequence (Blanchette et al., 2009).  
As well as being able to enter, survive, and multiply in both phagocytic and non-
phagocytic cells, L. monocytoegenes is also versatile in that it can cross the intestinal 
barrier, blood-brain barrier, and fetoplacental barrier in humans (Lecuit, 2005). Such an 
organism with a versatile, entry-inducing protein can surely provide great insight into 
versatile drugs which could enter a vast range of infected cells. Applying this pathogenic 
mimicry system to developing drugs is an important area of research that warrants further 
consideration because epithelial cells are often targets of intracellular pathogens such as 
L. monocytogenes (Schubert et al., 2002). Although it is known that InlA functionalized 
microparticles are digested by some non-phagocytotic epithelial cells, it would be useful 
to direct further research in comparing internalization rates of a large variety of non-
phagocytotic cells in order to demonstrate the range of target cell versatility of this 
method as a possible drug delivery option. With proper knowledge of mechanisms used 
by intracellular pathogens, drugs can be developed which can be easily internalized by 




MATERIALS AND METHODS 
 
Plasmid Preparation 
The pGEX-6p-1-InlA plasmid was created according to the protocol in Blanchette et al., 
2009, then freeze dried and stored at -20°C on filter paper. 
Plasmid Recovery and Initial DH5α Transformation 
The plasmid, which also contains a gene for ampicillin resistance (AmpR), was recovered 
by incubating the filter paper containing the plasmid in TE buffer (10 mM Tris-HCl, 1 
mM EDTA) obtained from Invitrogen (Carlsbad, CA). Escherichia coli MAX Efficiency 
DH5αF`IQ competent cells were purchased from Invitrogen (Carlsbad, CA), and 
transformed with the pGEX-6p-1-InlA plasmid according to the manufacturer’s protocol:  
The MAX Efficiency DH5αF`IQ competent cells were thawed on wet ice then mixed 
with the pGEX-6p-1-InlA plasmid TE buffer solution. As a negative control, another 
sample of DH5α competent cells was mixed with control M13mp19RF DNA solution, 
also from Invitrogen (Carlsbad, CA). The cells were incubated on ice for 30 minutes, 
heat-shocked for 45 seconds in a 42°C water bath, and then incubated on ice for an 
additional two minutes. S.O.C. medium and DH5αF`IQ lawn cells (Invitrogen, Carlsbad, 
CA),were added to the competent cells before plating on LB agar (10 g SELECT Peptone 
140, 5 g SELECT Yeast Extract, 5 g sodium chloride per liter media; Invitrogen, 
Carlsbad, CA),  plates containing ampicillin (50µg/ml), inverting, and incubating at 37°C 
overnight. The next day the plates were moved to the 4°C refrigerator in order to slow 
bacterial growth. Later, a single colony was picked and re-streaked in a four-way streak 
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manner onto a fresh LB plus ampicillin (50µg/ml) plate, incubated at 37°C overnight and 
transferred to the 4°C refrigerator once again. 
Plasmid Purification 
A Plasmid Purification Midi Kit was purchased from QIAGEN (Valencia, CA) and the 
accompanying manufacturer’s protocol was carried out to purify the InlA plasmid from 
the transformed DH5α E. coli cells: 
A single colony was picked from the selectively streaked DH5α plate and a starter culture 
was inoculated in 5 ml LB medium containing ampicillin (50µg/ml). The culture was 
incubated for approximately 8 hours at 37°C with vigorous shaking of approximately 300 
rpm. The starter culture was diluted 1/1000 into ampicillin (50µg/ml) selective LB 
medium (100 ml medium, 100 um starter culture) and grown at 37°C overnight with 
vigorous shaking of approximately 300 rpm. The bacterial cells were harvested by 
centrifugation at 6000 x g for 15 min at °4C. The bacterial pellet was re-suspended in 4ml 
of kit-provided Buffer P1. A volume of 4ml Buffer P2 was added, mixed thoroughly by 
vigorously inverting the sealed tube 6 times, and incubated at room temperature for 5 
minutes before 4ml of chilled Buffer P3 was added. Immediately upon addition of Buffer 
P3, the solution was mixed thoroughly by vigorously inverting 6 times then allowed to 
incubate on ice for 15 minutes. The solution was centrifuged at 20,000 x g for 30 minutes 
at 4° C, and the supernatant containing the plasmid was removed promptly. A 240 µl 
sample of the cleared lysate was saved for analytical gel sample in order to determine 
whether growth and lysis conditions were optimal. A QIAGEN-tip 100 was equilibrated 
by applying 4 ml of Buffer QBT and the column was allowed to empty by gravity flow. 
The previously isolated supernatant was applied to the QIAGEN-tip and allowed to enter 
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the resin by gravity flow. A 240 µl sample from the flow-through was saved for an 
analytical gel in order to determine the efficiency of DNA binding to the QIAGEN Resin. 
The QIAGEN-tip was then washed with 2 x 10 ml Buffer QC. A sample of 400 µl was 
taken from the combined wash fractions and saved for analytical gel. The DNA was 
eluted with 5 ml Buffer QF and a sample of 100 µl was saved for an analytical gel. The 
DNA was precipitated by adding 3.5 ml (0.7 volume) room-temperature isopropanol to 
the eluted DNA. It was then mixed and centrifuged immediately at 15,000 x g for 30 
minutes at 4°C and the supernatant was carefully decanted. The DNA pellet was washed 
with 2ml of room-temperature 70% ethanol and centrifuged at 15,000 g for 10 minutes. 
The supernatant was carefully decanted without disturbing the pellet. The pellets were 
then air dried for 10 minutes and the DNA was re-dissolved in 2 ml TE buffer. 
Absorbance readings were taken at 260 nm for determination of plasmid yield. Finally, 
the plasmid-TE buffer solution was split into four working aliquots of 0.5ml and stored in 
a -20°C freezer until it could be retransformed into One Shot BL21(DE3)pLysS 
expression competent E. coli cells according to the manufacturer’s protocol (Invitrogen, 
Carlsbad, CA).  
Agarose Gel  Electrophoresis 
Samples were taken throughout the midikit purification procedure and analyzed using gel 
electrophoresis. A 1% agarose gel was prepared and placed in the gel electrophoresis tank 
with 1X TBE buffer. Lane 1 was loaded with 1µl 1Kb Plus DNA ladder (Invitrogen, 
Carlsbad, CA), 3 µl TE buffer, and 1 µl BlueJuice Gel Loading Buffer (10X) (Invitrogen, 
Carlsbad, CA). The next 5 lanes were loaded with 4µl samples from the cleared lysate, 
flowthrough, wash fractions, elute, and purified plasmid from QIAGEN midi kit protocol, 
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each mixed with 1µl BlueJuice Gel Loading Buffer. The gel was run at 100 volts for 
approximately 45 minutes until the blue dye reached nearly the end of the gel. The gel 
was stained with 0.5 µl/ml Ethidium bromide water solution in the dark with gentle 
agitation for approximately 30 minutes. The gel was then de-stained with De-ionized 
water in the dark with gentle agitation for approximately 10 minutes before being 
transferred to a UV transilluminator for imaging. 
One Shot BL21(DE3)pLysS Transformation 
One Shot BL21(DE3)pLysS competent E. coli cells were purchased from Invitrogen 
(Carlsbad, CA), and transformed with the purified pGEX-6p-1-InlA plasmid according to 
the manufacturer’s protocol: 
 Two vials (50µl each) of BL21 cells were thawed on wet ice. One of the working 
aliquots of purified plasmid solution was thawed and the absorbance was taken again for 
accuracy of transformation. Approximately 2.0µl of the TE buffer plasmid solution, 
containing approximately 8.0 ng of pGEX-6p-1-InlA plasmid DNA was added to one of 
the vials of BL21 cells. Approximately 1µl of pUC19 control plasmid solution, 
containing approximately 10pg of plasmid was added to the other BL21 vial. Each vial 
was mixed separately by gentle tapping. The vials were incubated on ice for 30 minutes, 
heat shocked for 30 seconds in a 42°C water bath, then immediately placed on ice again. 
Each vial had added to it 250µl of room temperature S.O.C medium then placed in a 
shaking incubator at 37°C and 225 rpm for 1 hour. Samples of 50µl and 150µl of 
BL21(DE3)pLysS-pGEX-6P-1-InlA-1 E. coli cells transformed with the InlA plasmid 
were plated on two separate LB agar plates each containing ampicillin (50µg/ml) and 
chloramphenicol (34µg/ml). Two 50µl samples of BL21(DE3)pLysS cells transformed 
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with the pUC19 control plasmid were plated on two separate LB agar plates both 
containing ampicillin (50µg/ml) and chloramphenicol (34µg/ml). In order to check for 
phage contamination, 50µl of un-transformed BL21(DE3)pLysS E. coli cells were plated 
on an LB agar plate containing no antibiotics.  In order to verify for the absence of 
ampicillin resistance contamination, 50µl of un-transformed BL21(DE3)pLysS E. coli 
cells were plated on an LB agar plate containing ampicillin (50µg/ml). Finally, in order to 
verify the presence of the pLysS plasmid in the BL21(DE3)pLysS E. coli cells which 
confers chloramphenicol resistance and expresses the T7 lysozyme, 50 µl of un-
transformed BL21(DE3)pLysS E. coli cells were transformed on an LB agar plate 
containing chloramphenicol (34µg/ml). Each plate was inverted and incubated at 37°C 
overnight.  
InlA-GST Expression 
Colonies were selected from the 50µl spread plate of BL21(DE3)pLysS-pGEX-6P-1-
InlA-1 E. coli cells and diluted into liquid LB media containing 50µg/ml ampicillin and 
34µg/ml chloramphenicol. Four 5ml cultures were made containing 4 colonies each. The 
cultures were incubated at 37ºC and 225 rpm overnight in 50ml centrifuge tubes. The 
following day, the overnight cultures were diluted. Two of the tubes were diluted into 
250 ml of LB media each in separate 1 liter flasks containing ampicillin (50µg/ml) and 
chloramphenicol (34µg/ml), and the other two tubes were diluted together in 500 ml of 
LB media with ampicillin (50µg/ml) and chloramphenicol (34µg/ml) in a 2 liter flask. 
The cultures were incubated at 37ºC and 225 rpm, and after 2 hours the absorbance at 600 
nm (A600) was checked from each flask. When A600 was in the 0.04-0.06 range for each 
flask, InlA-GST expression was induced by adding 2mM IPTG (0.5ml of 1M IPTG stock 
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solution per 250ml of culture). The cells were allowed to grow at 37ºC and 225 rpm for 
an additional 4 hours until growth was stopped by placing on ice. The cultures were then 
transferred to six 50 ml centrifuge tubes and centrifuged at 4,500 rpm, 4 ºC for 30 
minutes in 4 rounds. The supernatant was discarded after each round and the final cell 





















Plasmid Recovery and Initial DH5α Transformation 
Several white colonies were observed in the LB ampicillin (50µg/ml) agar plate spread 
with MAX Efficiency DH5αF`IQ competent E. coli cells transformed with the pGEX-6p-
1-InlA ampicillin resistant plasmid (figure 1.0 A), while the DH5α  E. coli cells 
transformed with the control M13mp19RF plasmid DNA did not form colonies in the 
presence of ampicillin (50µg/ml) LB agar (figure 1.0 B).  
 
Figure 1.0. Escherichia coli MAX Efficiency DH5αF`IQ competent cells transformed with pGEX-6p-1-
InlA plasmid (A) and with control M13mp19RF plasmid (B). MAX Efficiency DH5αF`IQ competent cells 
were thawed on wet ice, mixed with pGEX-6p-1-InlA ampicillin resistant plasmid TE buffer solution (A) 
or with control M13mp19RF DNA solution (B), incubated on ice for 30 minutes, heat-shocked for 45 
seconds in a 42°C water bath, and incubated on ice for two minutes. Cells were added to S.O.C. medium 
and DH5αF`IQ lawn cells, plated on LB agar plates containing ampicillin (50µg/ml), inverted, and 








DH5α  E. coli cells transformed with pGEX-6p-1-InlA plasmid were cultured and 
pelleted using centrifugation. Alkaline lysis was used to break open the bacterial cells and 
expose the DNA. The plasmid DNA was bound to QIAGEN Anion-Exchange Resin 
under low-salt and pH conditions. The RNA, proteins, dyes, and low molecular weight 
impurities were removed by medium salt wash. The plasmid DNA was eluted in a high-
salt buffer and then concentrated and de-salted by isopropanol precipitation. The purified 
plasmid was then re-dissolved in 2 ml TE buffer and the absorbance of the sample was 
taken using spectrophotometer at 260 nm (A260) in order to determine the yield of 
purified plasmid. The average absorbance reading for the plasmid solution was 
A260=0.05. The concentration of purified plasmid in the TE buffer was found to be 
approximately 2.5µg/ml (Equation 1.0), and therefore the total yield of plasmid purified 
from the procedure was approximately 5µg (Equation 2.0). 
 
Equation 1.0. Calculation of purified plasmid concentration per ml TE buffer after QIAGEN midi kit 












Agarose Gel Electrophoresis 
The agarose gel electrophoresis image shows clear bands representing the 1Kb Plus DNA 
ladder (Figure 2.0 A) and samples 1-4 taken from the QIAGEN plasmid purification midi 
kit procedure including the cleared lysate containing supercoiled and open circular 
plasmid DNA and degraded RNA (Figure 2.0 B); flow-through fraction showing 
supercoiled (lower band) and open circular form (upper band) of the plasmid with 
denatured supercoiled DNA migrating just below the supercoiled form (Figure 2.0 C); 
Wash fractions (Figure 2.0 D); and the elute containing pure plasmid DNA with no other 
contaminating nucleic acids (Figure 2.0 E). The final purified plasmid stored in TE buffer 
also showed a clear band around the same distance as the elute as well as a faint upper 
band representing open circular DNA between 2.0kb and 5.0kb (Figure 2.0 F).  
 
 
Figure 2.0. Agarose gel electrophoresis analysis from plasmid purification. DH5α E. coli cells with InlA 
plasmid were cultured and pelleted using centrifugation. Alkaline lysis was used to break open the bacterial 
cells and expose the DNA. The plasmid DNA was bound to QIAGEN Anion-Exchange Resin under low-
salt and pH conditions. The RNA, proteins, dyes, and low molecular weight impurities were removed by 
medium salt wash. The plasmid DNA was eluted in a high-salt buffer and then concentrated and de-salted 
by isopropanol precipitation. (A) 1Kb Plus DNA ladder (Invitrogen). (B) Sample 1: Cleared lysate 
containing supercoiled and open circular  plasmid DNA and degraded RNA. (C) Sample 2: Flow-through 
fraction. Supercoiled (lower band) and open circular form (Upper band) of the plasmid with denatured 
supercoiled DNA migrating just below the supercoiled form. (D) Sample 3: Wash fractions. (E) Sample 4: 
Elute containing pure plasmid DNA with no other contaminating nucleic acids. (F) Final purified plasmid 
supercoiled form (lower dark band). Faint upper band shows open circular plasmid between 2kb and 5kb. 
The pGEX plasmid is around 4.9Kb. 
 18 
  
One Shot BL21(DE3)pLysS Transformation 
Approximately 8.0 ng of the purified ampicillin resistant pGEX-6P-1-InlA-1 plasmid was 
transformed into One Shot BL21(DE3)pLysS expression competent E. coli cells. 
Volumes of 50µl and 150µl of culture were plated onto LB agar plates containing 
ampicillin (50µg/ml) and chloramphenicol (34µg/ml). Both plates yielded abundant white 
colonies with the 150µl culture displaying a much denser area of growth (Figure 3.0 B) 
than the 50µl culture (Figure 3.0 A). Approximately 10 pg of control ampicillin resistant 
pUC19 plasmid was transformed into One Shot BL21(DE3)pLysS expression competent 
E. coli cells and a volume of 50µl culture was plated onto two LB agar plates containing 
ampicillin (50µg/ml) and chloramphenicol (50µg/ml). The first plate had 6 white colonies 
(Figure 3.0 C), and the second plate had 4 white colonies, yielding an average of 5 
pUC19 control colonies for the transformation efficiency. 50 µl of un-transformed 
BL21(DE3)pLysS E. coli cells was plated onto LB agar containing no antibiotics in order 
to check for phage contamination. The plate yielded a lawn of BL21 cells (Figure 3.0 E). 
50 µl of un-transformed BL21(DE3)pLysS E. coli cells was plated onto LB agar plates 
containing ampicillin (50µg/ml) in order to verify for the absence of ampicillin resistance 
contaimination. No colonies formed on the plate (Figure 3.0 F). 50 µl of un-transformed 
BL21(DE3)pLysS E.coli cells was plated onto LB agar containing chloramphenicol 
(34µg/ml)  in order to verify the presence of the pLysS plasmid in the BL21(DE3)pLysS 
cells which expresses the T7 lysozyme. Abundant colonies formed on the plate (Figure 




Figure 3.0. Transformation of One Shot BL21(DE3)pLysS competent E. coli cells (A) 50µl 
BL21(DE3)pLysS E. coli cells transformed with pGEX-6P-1-InlA-1 plasmid plated on LB agar plate 
containing ampicillin (50µg/ml) and chloramphenicol (50µg/ml). pLysS plasmid has chloramphenicol 
resistance and the InlA plasmid has ampicillin resistance. (B) 150µl BL21(DE3)pLysS E. coli cells 
transformed with pGEX-6P-1-InlA-1 plasmid plated on LB agar plate containing ampicillin (50µg/ml) and 
chloramphenicol (34µg/ml). (C, D) Replicates of 50µl BL21(DE3)pLysS E. coli cells transformed with 
pUC19 control ampicillin resistant plasmid plated on LB agar plates containing ampicillin (50µg/ml) and 
chloramphenicol (34µg/ml). (E) 50 µl un-transformed BL21(DE3)pLysS E. coli cells plated on LB agar 
containing no antibiotics. A lawn is apparent which confirms that there is no phage contamination. (F) 50 
µl un-transformed BL21(DE3)pLysS E. coli cells plated on LB agar  containing ampicillin (50µg/ml). Lack 
of growth verifies absence of ampicillin resistance contamination. (G) 50 µl un-transformed 
BL21(DE3)pLysS E. coli cells plated on LB agar  containing chloramphenicol (34µg/ml). Growth verifies 




The average number of colonies of BL21 transformed with the control ampicillin 
resistant pUC19 plasmid was used to calculate the transformation efficiency using the 
calculation provided in the One Shot BL21(DE3)pLysS user manual by Invitrogen 
(Carlsbad, CA). The transformation efficiency proved to be 3x10
6
 transformants per µg 
of plasmid DNA (Equation 3.0). 
 
Equation 3.0. Calculation of transformation efficiency of One Shot BL21(DE3)pLysS expression 
competent E. coli cells using the average number of colonies of BL21 cells transformed with the control 
ampicillin resistant pUC19 plasmid grown on LB agar plates containing ampicillin (50µg/ml) and 


















It has been shown that the pGEX-6p-1-InlA plasmid was successfully restored 
from its freeze-dried, filter paper storage condition and transformed into the Escherichia 
coli MAX Efficiency DH5αF`IQ competent cells (Figure 1.0). DH5α cells were 
transformed with either the pGEX-6p-1-InlA plasmid containing a gene for ampicillin 
resistance, or with the control M13mp19RF plasmid which did not confer ampicillin 
resistance. Both types of cells were plated onto LB agar plates containing ampicillin 
antibiotic (50µg/ml). The plates were inverted, and incubated overnight at 37°C. Only the 
plate containing the DH5α cells transformed with the pGEX-6p-1-InlA plasmid formed 
bacterial colonies, confirming that the ampicillin resistant plasmid was in fact 
transformed in the DH5α cells, which would otherwise not have grown in the presence of 
ampicillin. This initial transformation into DH5α was important to increase the stability 
of the InlA inserted gene and plasmid, and also to improve the quality of the DNA for 
following InlA-GST expression (Invitrogen, 2006). The plate containing DH5α cells 
transformed with the control M13mp19RF plasmid did not form colonies, because the 
cells could not grow in the presence of ampicillin, as the control plasmid did not confer 
ampicillin resistance. This also demonstrated that the ampicillin antibiotic was functional 
and had not degraded throughout the process, and was therefore a reliable means to 
selectively grow cells containing the plasmid of interest.  
The results of the agarose gel electrophoresis show that the pGEX-6p-1-InlA was 
successfully purified from the DH5α cells as the same clearly defined band located 
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between 1.0kb and 1.65kb became more pronounced from the elution sample (Figure 2.0. 
E), to the concentrated final purified product in TE buffer (Figure 2.0. F). The distinct 
upper band found in both Figure 2.0 E and F between 2.0kb and 5kb represents the open 
circular form of the plasmid. The pGEX plasmid is approximately 4.9 kb, but since the 
DNA ladder used was linear DNA, the base pair measurement of the open circular 
plasmid DNA is closer to the actual size of the plasmid than the base pair measurement of 
the closed circular plasmid DNA. When the final purified plasmid was re-dissolved in 
2ml TE buffer, absorbance readings were taken to ascertain the total yield of the plasmid. 
Using Equation 1.0 and Equation 2.0, it has been shown that the QIAGEN plasmid 
purification midi kit procedure yielded approximately 5µg purified pGEX-6P-1-InlA 
plasmid total, 8.0 ng of which was transformed into One Shot BL21(DE3)pLysS E. coli 
cells for expression of the InlA-GST fusion protein.  
The purified plasmid pGEX-6p-1-InlA was successfully transformed into the 
BL21 cells (Figure 3.0 A,B). The BL21(DE3)pLysS expression competent E. coli cells 
grew on LB agar containing ampicillin which directly suggests that the pGEX-6p-1-InlA, 
which confers ampicillin resistance (AmpR), was present in the BL21 cells when plated 
onto the LB agar. If the ampicillin resistant plasmid had not been successfully 
transformed into the cells, no colonies would have grown in the presence of the 
ampicillin. The BL21 cells also grew in the presence of chloramphenicol, which directly 
suggests that the pLysS plasmid was also present in the cells, since this plasmid carries a 
gene for chloramphenicol resistance (CamR). The presence of pLysS is important 
because it expresses the T7 lysozyme needed to lower background expression level of 
InlA before it is needed. The DE3 lysogen carried by BL21(DE3)pLysS strain expresses 
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a T7 RNA polymerase under the control of lacUV5 promoter, so that only after IPTG is 
added will expression of InlA-GST commence (Invitrogen, 2010). In this way I was able 
to control when InlA-GST expression would occur.  
BL21 transformation with 10 pg control ampicillin resistant pUC19 plasmid was 
carried out in order to ascertain a transformation efficiency of 3x10
6 
transformants per µg 
plasmid DNA, which is slightly less than the expected transformation efficiency for 
BL21(DE3)pLysS of 10
8
 transformants per µg of supercoiled plasmid (Invitrogen, 2010). 
Un-transformed BL21 cells plated onto LB agar plates containing no antibiotics formed a 
dense lawn of bacterial growth which suggests that there was no phage contamination in 
the BL21 cultures. Un-transformed BL21 cells plated onto LB agar containing ampicillin 
(50µg/ml) did not form any colonies, because while the inherent pLysS plasmid confers 
chloramphenicol resistance, the BL21 cells did not contain any plasmid which would 
bestow ampicillin resistance, such as the pGEX-6p-1-InlA or the pUC19 plasmid. 
However, the un-transformed BL21 cells did in fact grow colonies on LB agar containing 
chloramphenicol (34µg/ml), showing that the pLysS plasmid was present in the BL21 
cells and that the T7 lysozyme would be expressed, lowering the background expression 
level of InlA-GST until the appropriate time.  
Finally, Expression of InlA-GST fusion protein was stimulated by adding IPTG to 
liquid cultures of BL21(DE3)pLysS-pGEX-6P-1-InlA-1 E. coli, activating the lacUV5 
promoter and T7 RNA polymerase. The cultures were centrifuged and the cell pellets 
were frozen at -20°C until bacterial lysis and protein extraction could be carried out. 
Freezing the cell pellets also aids in the subsequent lysis process. Purification of the InlA-
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GST fusion protein from the cell pellet will need to be carried out before the expression 
of InlA-GST can be absolutely confirmed. Thereafter Western blotting can be applied.  
The future steps in our study will be to purify the InlA-GST protein from the 
BL21 cells using glutathione affinity based chromatography. The InlA protein contains a 
GST tag, so a Pierce GST Spin Purification Kit will be used to isolate the InlA-GST. The 
GST will then be cleaved from the InlA. The GST will remain bound to the glutathione 
resin column while the InlA will filter through, yielding purified InlA protein. The InlA 
will then be fluorescently labeled with Alexa Flour dye and bound to different sizes of 
microbeads in varying densities by passive adsorption.  
The InlA functionalized beads will then be used to study the phagocytosis process 
in several epithelial cell line cultures in order to compare the effects of ligand density, 
bead size, and eukaryotic target cell versatility. The endocytosis process and kinetics will 
be analyzed by flow cytometry and fluorescent microscopy for each cell line to compare 
internalization rates. It has already been shown that internalization of InlA functionalized 
beads can be achieved in at least some epithelial eukaryotic cell lines (Blanchette et al., 
2009). We are therefore applying the protocols in this previous study and expanding on 
this idea by demonstrating that this method can be applied to a vast range of epithelial 
cells. In doing so, we can ensure that this method of intracellular delivery can be used 
consistently among different individual cell types and could be a promising efficient drug 
delivery option in the future. The implications of our study are great, because it is 
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